These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 24833494)

  • 41. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
    Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
    Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
    Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
    Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
    Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
    J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
    Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
    Minamimoto R; Toyohara J; Seike A; Ito H; Endo H; Morooka M; Nakajima K; Mitsumoto T; Ito K; Okasaki M; Ishiwata K; Kubota K
    J Nucl Med; 2012 Feb; 53(2):199-206. PubMed ID: 22190643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer.
    Han EJ; Yang YJ; Park JC; Park SY; Choi WH; Kim SH
    Nucl Med Commun; 2015 Dec; 36(12):1187-94. PubMed ID: 26375438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer.
    Xu X; Yu J; Sun X; Yang G; Li K; Fu Z; Han A; Zheng J
    Am J Clin Oncol; 2008 Oct; 31(5):470-5. PubMed ID: 18838884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
    Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
    Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
    Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.